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SETD2 and histone H3 lysine 36 methylation deficiency in
advanced systemic mastocytosis
G Martinelli1,20, M Mancini1,20, C De Benedittis1,21, M Rondoni2,21, C Papayannidis1, M Manfrini1, M Meggendorfer3, R Calogero4,
V Guadagnuolo1, MC Fontana1, L Bavaro1, A Padella1, E Zago5,6, L Pagano7, R Zanotti8,9, L Scaffidi8,9, G Specchia10, F Albano10,
S Merante11, C Elena11, P Savini12, D Gangemi13, P Tosi14, F Ciceri15,16, G Poletti17, L Riccioni18, F Morigi18, M Delledonne5,6, T Haferlach3,
M Cavo1, P Valent19 and S Soverini1
The molecular basis of advanced systemic mastocytosis (SM) is not fully understood and despite novel therapies the prognosis
remains dismal. Exome sequencing of an index-patient with mast cell leukemia (MCL) uncovered biallelic loss-of-function mutations
in the SETD2 histone methyltransferase gene. Copy-neutral loss-of-heterozygosity at 3p21.3 (where SETD2 maps) was subsequently
found in SM patients and prompted us to undertake an in-depth analysis of SETD2 copy number, mutation status, transcript
expression and methylation levels, as well as functional studies in the HMC-1 cell line and in a validation cohort of 57 additional
cases with SM, including MCL, aggressive SM and indolent SM. Reduced or no SETD2 protein expression—and consequently, H3K36
trimethylation—was found in all cases and inversely correlated with disease aggressiveness. Proteasome inhibition rescued SETD2
expression and H3K36 trimethylation and resulted in marked accumulation of ubiquitinated SETD2 in SETD2-deficient patients but
not in patients with near-normal SETD2 expression. Bortezomib and, to a lesser extent, AZD1775 alone or in combination with
midostaurin induced apoptosis and reduced clonogenic growth of HMC-1 cells and of neoplastic mast cells from advanced SM
patients. Our findings may have implications for prognostication of SM patients and for the development of improved treatment
approaches in advanced SM.
Leukemia (2018) 32, 139–148; doi:10.1038/leu.2017.183
INTRODUCTION
Systemic mastocytosis (SM) is characterized by abnormal growth
and accumulation of mast cells (MCs) and their precursors in the
bone marrow (BM) and in other organs.1 On the basis of clinical
variables and signs of organ damage the WHO classification
defines a spectrum of disease variants, including indolent SM
(ISM), smoldering SM (SSM), SM with associated hematologic (non-
MC) neoplasm (SM-AHN), aggressive SM (ASM) and MC leukemia
(MCL).2–4 Clinical features and courses in patients with SM vary
greatly. In those with ISM and SSM, the clinical course is usually
stable and symptoms mostly relate to MC degranulation and
mediator release.1 In contrast, ASM and MCL are characterized by
organ damage resulting from malignant MC infiltration. Whereas
patients with ISM are considered to have a normal life expectancy,
ASM and MCL are severe, fatal forms of SM with short survival
times. Therapeutic options are limited in these patients. Somatic
mutations leading to ligand-independent activation of the
receptor tyrosine kinase KIT (most frequently, KIT D816V) are
considered to promote MC differentiation and survival and thus
have an important pathogenetic role in SM.5 However, KIT D816V
is detectable both in ASM and in most patients with ISM6 and
several lines of evidence suggest that KIT D816V alone is not a
fully transforming oncoprotein.7,8 The investigation of a panel of
candidate genes involved in myeloid neoplasms has recently
shown that additional mutations in genes other than KIT (TET2,
NRAS, ASXL1, DNMT3A, SRSF2, CBL, ASXL1) may indeed be found
in advanced SM, including SM-AHN and ASM.9–11 Patients
with additional mutations in ASXL1, RUNX1 and SRSF2 were
found to have a significantly shorter overall survival.12–15 However,
only one study using genome-wide approaches to screen for
novel molecular aberrations in advanced SM (ASM or MCL) has
been published to date.16 This prompted us to undertake
an integrated molecular genetic study of a MCL case who
was referred to our center, with the aim to identify novel,
potentially druggable lesions involved in the pathogenesis of
advanced SM.
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MATERIALS AND METHODS
Patient samples and cell lines
The index MCL case and 57 SM patients subsequently included in the
validation cohort based on sample availability (23 patients with ISM (three
with SM-AHN), three with SSM, 20 with ASM (three with ASM-AHN) and 11
with MCL (two with MCL-AHN)) were diagnosed and classified according to
WHO criteria.2–4 The clinical characteristics of each patient are shown in
Supplementary Table 1. In the index case, CD117+ cells were isolated from
BM mononuclear cells (MNCs) collected at the time of diagnosis by
immunomagnetic cell separation (Miltenyi Biotech, Cologne, Germany)
followed by RNA, DNA and protein extraction with the AllPrep DNA/RNA/
Protein Kit (Qiagen, Hilden, Germany). Germline DNA was obtained from
saliva. In the validation cohort, DNA, RNA and proteins were obtained from
CD117+ cells or MNCs from BM. In this cohort, patients with acute myeloid
leukemia-type AHN were excluded. As a result, almost all CD117+ cells
isolated from BM samples were CD34-/CD117+ MCs. Investigators
performing the experiments were blinded with respect to the WHO
subtype, clinical features and outcome of the patients. Sample and data
collection were approved by the Institutional Review Boards of the S.
Orsola-Malpighi Hospital (protocol 112/2014/U/Tess) and the participating
institutions. All patients gave written informed consent. The mast cell line
HMC-1, generated from a patient with MCL, was kindly provided by Dr
Joseph Butterfield (Mayo Clinic, Rochester, MN, USA). The cell line has two
subclones, HMC-1.1 harboring the V560G KIT mutation, and HMC-1.2
harboring both the V560G and the D816V KIT mutations.17,18 The control
cohort included 95 healthy individuals with age ranging from 20 to
95 years.
Whole-exome sequencing (WES) and single-nucleotide
polymorphism (SNP)-arrays
For the index case, paired-end DNA libraries were prepared from CD117+
cells and from saliva using the TruSeq DNA Sample preparation kit
(Illumina, San Diego, CA, USA). Exon-coding sequences were captured
using TruSeq Exome Enrichment Kit (Illumina) and sequenced on an HiSeq
1000 (Illumina). SNP-array analysis was performed in the index case and in
13 additional cases of the validation cohort (8 MCL, 4 ASM, 1 ISM) using the
CytoScan HD array (Affymetrix, Santa Clara, CA, USA). Protocols and data
analysis are described in the Supplementary Information.
Loss-of-heterozygosity (LOH) analysis at 3p21.3
Genotyping of nine single-nucleotide polymophisms with minor allele
frequency 440% in the minimal common region of LOH (rs11720139,
rs2305634, rs2305635, rs1079276, rs2278963, rs6767907, rs4082155,
rs6780013, rs1531875) was performed by direct sequencing as detailed
in the Supplementary Information.
SETD2 mutation screening
SETD2 mutations identified by WES in the index case were validated by
Sanger sequencing at the DNA and mRNA level using primers shown in the
Supplementary Information. Screening of SETD2 coding and promoter
sequences in the HMC-1 cell line and in the validation cohort was
performed by Sanger sequencing or high throughput sequencing as
described in the Supplementary Information.
Quantitative reverse transcription (RT)-PCR for SETD2 expression
In the HMC-1 cell line and in the 57 samples of the validation cohort, SETD2
expression was assessed by quantitative RT-PCR. Total RNA (200 ng) was
reverse transcribed to cDNA with the High-Capacity cDNA Reverse
Transcription Kit (Thermo Fisher Scientific, Waltham, MA, USA). Assays
were performed in triplicate on the ABI 7900HT system (Thermo Fisher
Scientific) using pre-designed TaqMan Gene Expression Assays (Thermo
Fisher Scientific) for SETD2 (Hs01014784_m1) and TBP (Hs00427621_m1) as
control gene. SETD2 mRNA levels were quantified using the Comparative
Ct method, using a pool of 10 healthy donors of various ages as calibrator.
Methylation analysis of the SETD2 promoter
Methylation status at the SETD2 promoter was assessed in the validation
cohort using EpiTect Methyl II PCR Assays (EPHS110216-1A; Qiagen) on an
ABI PRISM 7900HT, according to manufacturer’s instructions. A methylation
sensitive (EPHS115450-1A) and methylation dependent (EPHS115451-1A)
control assay were also run for all the samples analyzed. A pool of 10
healthy donors of various ages served as a negative control.
Drug treatments
After 24 hours of exposure of HMC-1.1 and HMC-1.2 cells to 1 μM AZD1775
(Selleckchem, Houston, TX, USA), 1 μM midostaurin (Selleckchem), 10 nM
bortezomib (Selleckchem), 1 μM AZD1775+1 μM midostaurin and 10 nM
bortezomib+1 μM midostaurin, apoptotic cell death was assessed by
measuring the uptake of fluoresceinated Annexin V and propidium iodide
(PI) (Roche Diagnostics, Mannheim, Germany). A FACsCantoII flow
cytometer (Beckton Dickinson, Franklin, NJ, USA) set at 488 nm excitation
and 530 nm wavelength bandpass filter for fluorescein detection or
580 nm for PI detection, and a dedicated software (DIVA software; Beckton
Dickinson) were used. Drug cytotoxicity was evaluated in clonogenic
assays. In HMC-1.1 and HMC-1.2, the reduction of colony (generated in
0.9% methylcellulose supplemented with 30% fetal calf serum) number in
the presence of increasing sublethal doses of AZD1775 (0.025–0.1 μM),
midostaurin (0.025–0.1 μM), AZD1775+midostaurin (0.025–0.1 μM each),
bortezomib (0.25–1 nM), bortezomib+midostaurin (0.25–1 nM)+(0.025–
0.1 μM) was assessed after 10 days of incubation at 37 °C in a fully
humidified atmosphere and 5% CO2. AZD1775 (0.025–0.1 μM), midostaurin
(0.025–0.1 μM), AZD1775+midostaurin (0.025–0.1 μM each), and bortezomib
(0.25–1 nM) were also tested in cells from three advanced SM patients (2
with MCL and one with ASM). Cells from two healthy donors were treated
for comparison. Nonlinear regression analyses performed using the
CompuSyn software19 (ComboSyn, Inc; Paramus, NJ, USA) were used to
calculate the efficacy of different drugs alone or in combination in cell lines
and in primary patient cells. Combination indexes were calculated using
the same software.
Co-immunoprecipitation/immunoblotting and western blotting
analyses
Co-immunoprecipitation/immunoblotting and western blotting were
performed as described in the Supplementary Information using the
following antibodies: anti-SETD2 (Abnova, Taipei, Taiwan), anti-H3K36Me3
(Merck Millipore, Darmstadt, Germany), anti-RNAPol II (Merck Millipore),
anti-hnRNP (Merck Millipore), anti-SUMO (Cell Signaling Technology,
Danvers, MA, USA) and anti-ubiquitin (Bethyl Laboratories, Montgomery,
TX, USA). Beta-actin (Santa Cruz Biotechnology, Dallas, TX, USA) and
Histone H3 (Merck Millipore) were used as loading controls. Immunor-
eactive proteins were visualized by probing with horseradish peroxidase-
conjugated secondary antibodies and then by enhanced chemilumines-
cence (ECL; Thermo Fisher Scientific). Immunoblots were scanned and
band intensities were quantified with the ImageJ software. Signal
intensities in single blots obtained from three individual experiments
were averaged, normalized to those of the loading controls and expressed
as a fraction of the intensities, set to 1, obtained in a pool of 10 healthy
donors of various ages used as a control.
Immunohistochemistry (IHC)
Immunohistochemistry (IHC) was performed on sections from paraffin-
embedded trephine BM biopsies of selected SM cases. IHC Staining with
anti-SETD2 antibody (HPA042451, Sigma-Aldrich, Milan, Italy; 1:30 dilution)
was performed using the Ventana BenchMark Ultra automated IHC slide
staining system (Ventana Medical Systems, Tucson, AZ, USA). Tissues from
normal testis and from a testicular seminoma were used as external
controls and to determine the antibody dilution giving the best staining
results. Antibody reactivity was visualized with diaminobenzidine. Slides
were counterstained with hematoxylin.
Statistical analysis
Analysis of variance followed by Tukey post-hoc test was applied in order
to detect differences in SETD2 and H3K36Me3 expression between groups.
Spearman correlation index was calculated between SETD2 and H3K36Me3
level and disease subtype. Differences in the distribution of continuous
and categorical variables between SETD240.5 and o0.5 subgroups were
assessed by means of non-parametric tests—the Mann–Whitney U-test
and the Fisher’s exact test, respectively. There was no adjustment for
multiple testing as all analyses were explorative. Survival analysis was
considered from the date of diagnosis to the date of death or last contact.
Survival curves were prepared by the Kaplan and Meier method and
statistical significance of differences in survival was calculated by the log-
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rank test. Analyses were carried out by SPSS (IBM Corp, Chicago, IL, USA)
and R.20 All P-values were two-sided and those less than 0.05 were
considered statistically significant.
RESULTS
WES of the index MCL case identifies loss of function mutations in
SETD2
Among the mutated genes found in neoplastic MCs but not in
saliva, SETD2 stood out among others because of its known role as
a tumor suppressor and its involvement in various solid tumors
and in acute leukemias.21,22 Notably, two distinct putatively
inactivating heterozygous mutations were identified in the
patient, a nonsense mutation in exon 15 (NM_014159:c.G6753T:
p.Glu2234Ter) and a frameshift insertion in exon 20 (NM_014159:
c.7595_7596insC:p.Gly2515ArgfsTer5) (Figures 1a and b). Cloning
of a cDNA fragment encompassing both mutant residues showed
that the mutations were biallelic. The first mutation was predicted
to result in a truncated protein lacking 330 amino acids at the
C-terminal, whereas the second mutation was predicted to result
in a truncated protein lacking 46 amino acids at the C-terminal.
Western blotting, however, showed that only the SETD2-truncated
isoform resulting from the nonsense mutation was expressed in
neoplastic MCs (Figure 1c). This truncated protein (tSETD2) lacked
the highly conserved SRI domain (Figure 1b). The normal SETD2
protein is responsible for trimethylation of lysine 36 of histone H3
(H3K36Me3).23 Co-immunoprecipitation showed that tSETD2 lost
the ability to bind the H3 histone and, most importantly, western
blotting showed that H3K36Me3 was abrogated (Figure 1c). The
SRI domain is also known to mediate SETD2 interaction with the
phosphorylated C-terminal domain of the RNA polymerase II large
subunit24–26 and with the heterogeneous nuclear ribonucleopro-
tein-L,27 thus coupling H3K36Me3 with transcription and splicing.
Co-immunoprecipitation confirmed that tSETD2 did not bind
either protein (Figure 1c), further underpinning the loss of
function nature of the SETD2 mutations found in the index case.
LOH at the SETD2 locus is detectable in SM patients
The SETD2 gene maps to chromosome 3p21, where allelic loss due
to deletions or copy neutral (CN)-LOH has frequently been
observed in kidney, lung, breast and many other cancer samples
and cell lines.28 We thus examined the copy number status and
searched for LOH at 3p21 in 13 cases of the validation cohort
(eight MCL, four ASM, one ISM) for whom SNP-array data were
available. CN-LOH of a small region ranging from 613 kb to
2.02 Mb at 3p21.3 was found in 10/13 cases (7 MCL, 2 ASM, 1 ISM).
The minimal common region (MCR) of LOH included SETD2 and
nine additional genes (CCDC12, NBEAL2, NRADDP, KIF9-AS1, KIF9,
KLH18, PTPN23, SCAP, ELP6) (Supplementary Figure 1). We thus
extended the screen for LOH specifically at 3p21.3 in the
remaining patients of the validation cohort. Genotyping of nine
SNPs with minor allele frequency440% in the MCR was
suggestive of LOH in 17 additional cases. Thus, overall, LOH was
Figure 1. SETD2 loss of function mutations in the index MCL case (MCL1). (a) Sanger sequencing chromatograms with the frameshift (top) and
nonsense (bottom) mutations identified by whole-exome sequencing. (b) Localization of the mutations with respect to the key functional
domains of the SETD2 protein. The SRI domain is necessary for histone H3 lysine 36 trimethylation (H3K36Me3) and mediates SETD2
interaction with the phosphorylated C-terminal domain of the RNA polymerase II large subunit (RNA pol II) and with the heterogeneous
nuclear ribonucleoprotein-L (HnRNP), thus coupling H3K36Me3 with transcription elongation and splicing. (c) from top to bottom: western
blotting (WB) showing the truncated SETD2 (tSETD2) protein as compared to full-length SETD2 detectable in a pool of proteins from
mononuclear cells of healthy donors; co-immunoprecipitation experiments performed by using: an anti-RNA pol II, an anti-hnRNP and an anti-
histone H3, respectively, to isolate the proteins of interest and then an anti-SETD2 as primary antibody to label the PVDF membrane on which
the immunoprecipitates were transferred; WB for H3K36Me3. Histone H3 and actin were used as loading controls.
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detected in 27/57 (47%) SM patients, namely in 8/11 (72%) MCL-,
11/20 (55%) ASM-, 1/3 SSM- and 7/23 (30%) ISM patients
(Supplementary Table 2).
SETD2 and H3K36Me3 deficiency are recurrent events in SM and
cluster in advanced disease
To investigate the frequency of SETD2 inactivation in the
validation cohort, we used western blotting to assess H3K36Me3
levels as a surrogate marker of loss of SETD2 function and to
screen for the expression of SETD2 full-length vs truncated
isoforms. No evidence of abnormal isoforms was found. However,
the SETD2 protein turned out to be reduced or not at all expressed
in the great majority of patients examined (Figure 2a). H3K36Me3
paralleled SETD2 expression and was reduced or absent accord-
ingly (Figure 2a). In one MCL, one ASM and two ISM patients,
SETD2 and H3K36Me3 levels were assessed in total MNC fractions
obtained from BM and in purified CD117+ cells in parallel and no
differences were observed. To confirm western blotting results,
IHC with an anti-SETD2 antibody was performed on BM trephine
biopsies of patients displaying various SETD2 protein levels. The
intensity of nuclear staining and the percentage of immunos-
tained atypical MCs varied among the cases and were consistent
with SETD2 protein expression as assessed by western blotting
(Supplementary Figure 2). Internal positive controls (BM myeloid
precursors and megakaryocytes) were present in each case and
confirmed the specificity of the stain.
Median SETD2 and H3K36Me3 levels, assessed by densitometric
analysis of western blotting results (Supplementary Table 3), were
significantly correlated with each other (Spearman R= 0.91,
Po0.001) and were lower in advanced SM (R= 0.57, Po0.001)
(Figures 2b and c). In particular, patients with MCL and ASM
displayed significantly lower levels of SETD2 and H3K36Me3 as
compared to ISM (SETD2: P=o0.001 and P= 0.002, respectively;
H3K36Me3: P⩽ 0.001 and P= 0.004, respectively). There seemed to
be no differences in SETD2 expression between advanced SM
patients with (n= 8) or without (n= 26) AHN. When the distribu-
tion of SETD2 protein levels within the ASM and ISM subgroups
was examined, no significant differences regarding baseline
clinical variables or survival emerged between cases with SETD2
o0.5 and 40.5 (data not shown). However, when patients with
SETD240.5 and o0.5 were compared regardless of disease
subtype, lower SETD2 expression was found to be associated with
older age (P= 0.02), higher serum tryptase levels (P= 0.03), lower
hemoglobin (P= 0.03) and platelet count (P= 0.005). In addition,
patients with lower SETD2 levels were more likely to have
splenomegaly (P= 0.04) and less likely to have skin lesions
(P= 0.03). There was also a trend towards shorter overall survival
(P= 0.06) (data not shown). There seemed to be no preferential
association between SETD2 loss of function and the presence or
absence of specific additional mutations or mutation patterns in
myeloid genes (for example, SF3B1, SRSF2, TET2, ASXL1 and so on;
Supplementary Table 4).
In an attempt to explain the nonrandom accumulation of LOH
at 3p21.3 and the observed SETD2 protein deficiency, we
sequenced the entire SETD2 gene, including the promoter region,
in all the patients of the validation cohort. Only one ASM patient
(who had no evidence of 3p21.3 LOH) had a missense mutation
Figure 2. SETD2 protein and H3K36Me3 deficiency in SM. (a) representative western blot results for SETD2 protein and H3K36Me3 levels in SM
patients as compared to a pool of healthy donors (HDs). One of three independent experiments is shown. (b and c) Box and whiskers plots of
SETD2 and H3K36Me3 level estimates obtained by densitometric analysis of western blots. Median, interquartile range, minimum, maximum
and outliers are indicated. SETD2 and H3K36Me3 signal intensities in single blots obtained from three individual experiments were normalized
to those of beta-actin and H3 histone, respectively, and averaged. Normalized SETD2 and H3K36Me3 levels calculated in SM patients were
then expressed in comparison to normalized SETD2 and H3K36Me3 levels detected in a pool of HDs, conventionally set to 1. The asterisks
indicate that MCL and ASM had significantly lower levels of SETD2 protein (Po0.001 and P= 0.002, respectively) and H3K36Me3 (Po0.001
and P= 0.004, respectively) as compared to ISM.
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(c.1351A4G; p.Thr451Ala) not reported as a SNP (Supplementary
Table 5). The mutation was not found either in the Catalogue of
Somatic Mutatons in Cancer or in ClinVar databases and was
predicted to be benign/tolerated by Mutation Taster and
Polyphen-2. Thus, despite LOH, the classical two-hit hypothesis
of tumor suppressor gene inactivation was found not to be the
case for SETD2 in SM.
We then assessed whether promoter hypermethylation might
be responsible for SETD2 protein deficiency, in the presence or
absence of LOH. Analysis of the SETD2 promoter showed o1%
methylated DNA in all the patients of the validation cohort.
Methylation levels were not different from those of healthy
donors. Other mechanisms of transcriptional down-regulation
were excluded, since SETD2 mRNA levels were not significantly
lower in the validation cohort as compared to healthy donors.
To rule out the possibility that SETD2 loss of function might be
another age-associated alteration in an epigenetic regulator,29–31
80 healthy older adults with an age ranging from 65 to 95 years
were screened for SETD2 mutations and for alterations in SETD2
protein expression or H3K36Me3. No sequence variants other than
the Pro1962Leu and the Asn1155Asn SNPs were detected. All the
older adults did express SETD2; and densitometric analysis of
western blots (done using a pool of 10 younger adults with an age
ranging from 20 to 30 years as a calibrator, after having excluded
inter-individual variations of expression) showed comparable
SETD2 and H3K36Me3 levels among individual older adults
as well as between older and younger adults (Supplementary
Table 6).
We next wondered whether the HMC-1 cell line, established
from a patient with MCL, also exhibits SETD2 and H3K36Me3
deficiency. Indeed, western blotting revealed no SETD2 protein
and no H3K36Me3 in either subclone (Figure 3a). Sequencing
ruled out the presence of SETD2 gene mutations. Similarly to the
patients of the validation cohort, both HMC-1.1 and HMC-1.2 cells
were found to have no significant reduction in SETD2 transcript
levels as compared to SETD2 wild-type cell lines and the gene
promoter was found to have very low methylation levels (4.08%
and 1.08% in HMC-1.1 and HMC-1.2, respectively). This suggested
that similar mechanism(s) acting at the translational or post-
translational level underlie SETD2 deficiency in advanced SM
patients and in HMC-1 cells.
SETD2 deficiency results from enhanced proteasomal degradation
In HMC-1 cells, incubation with the proteasome inhibitor
bortezomib (10 nM for 24 h) rescued SETD2 protein expression
and restored H3K36Me3 levels (Figure 3b), indicating that a
functional SETD2 protein is regularly translated in neoplastic MCs,
and that failure to detect it by western blotting is rather due
to altered turnover and proteasomal degradation. Co-
immunoprecipitation with an anti-SETD2 antibody after bortezo-
mib treatment showed that blockage of proteasome-mediated
degradation results in accumulation of ubiquitinated and SUMOy-
lated SETD2 (Figure 4a). We therefore speculated that reduced or
undetectable SETD2 expression in advanced SM patients might be
accounted for by hyper-ubiquitination and -SUMOylation leading
to proteasomal degradation. We thus compared the effects of
proteasome inhibition in malignant MCs from advanced SM
patients displaying no SETD2 protein and from ISM patients with
near-normal SETD2 levels. In contrast to SETD2-deficient patients,
where results were superimposable to those obtained in HMC-1
cells, patients with near-normal SETD2 expression had similar
levels of ubiquitinated and SUMOylated SETD2 protein (and
similar H3K36Me3 levels) before and after the inhibition of
proteasome-mediated degradation (Figure 4b).
Bortezomib and the combination of Midostaurin+AZD1775 reduce
colony growth and induce apoptosis in HMC-1 cells
Given the ability of bortezomib to rescue SETD2 expression and
H3K36Me3, we tested whether proteasome inhibition might be
effective in vitro in HMC-1 cells. Bortezomib as single agent
strikingly inhibited colony formation (LD50 in HMC-1.1 = 0.173 nM;
LD50 in HMC-1.2 = 0.226 nM)(Figure 5a) and induced apoptosis in
these cells (Figures 5f and g). Combination with D816V KIT
tyrosine kinase inhibition by midostaurin32,33 did not increase
significantly bortezomib efficacy (Supplementary Figure 3).
Recently, a synthethic lethality interaction between H3K36Me3
deficiency and enhancement of replicative stress via Wee1 G2
checkpoint Serine/Threonine protein kinase inhibition has been
uncovered.34 As a consequence, inhibition of Wee1 with AZD1775
was found to kill SETD2/H3K36Me3-deficient cells.34 We thus
decided to explore also the in vitro efficacy of a strategy using
AZD1775 alone or in combination with midostaurin in HMC-1 cells.
AZD1775+midostaurin combination suppressed colony growth
with a LD50 of 0.036 μM and 0.038 μM for HMC-1.1 and -1.2,
respectively (Figure 5b; results of AZD1775 and midostaurin as
single agents shown in Figures 5c and d; summary of LD50 values
in Figure 5e). When compared to either agent alone, AZD1775
+midostaurin combination displayed a strong synergistic effect in
apoptotic cell death induction in HMC-1.1 cells, whereas only an
additive effect was observed in HMC-1.2 cells (Supplementary
Table 7).
Bortezomib and the combination of AZD1775+midostaurin reduce
the clonogenic potential of SETD2/H3K36Me3-deficient neoplastic
MCs
We next assessed the effects of bortezomib, AZD1775, midos-
taurin and AZD1775+midostaurin combination on the clonogenic
potential of neoplastic MCs from two patients with MCL with no
SETD2 expression (MCL3 and MCL7) and one patient with ASM
(ASM18) with very low SETD2 expression (20% as compared to a
pool of healthy donors). Growth inhibition curves and LD50 values
Figure 3. SETD2 protein and H3K36Me3 levels in HMC-1.1 and -1.2 cell lines before and after inhibition of proteasome-mediated degradation.
(a) SETD2 and H3K36Me3 levels as detected by western blotting in HMC-1.1 and HMC-1.2 cells compared to K562 cells. (b and c) Effect of
proteasome inhibition by bortezomib on SETD2 and H3K36Me3 levels in HMC-1.1 and HMC-1.2. One of three independent experiments is
shown in all panels.
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are shown in Figure 6. Bortezomib induced a marked dose-
dependent reduction in colony formation with LD50 ranging from
0.105 to 0.295 nM (Figure 6a). The combination of AZD1775
+midostaurin appeared to be slightly superior to the single agent
strategy in MCL3 and ASM18, with LD50 values of 0.054 and
0.058 μM, respectively, but not in MCL7 where AZD1775 as single
agent showed the lowest LD50 (0.026 μM for AZD1775 alone as
against 0.048 μM for the combination; Figures 6b–e).
DISCUSSION
In recent years, deregulation of epigenetic modifiers by chromo-
somal translocations, genomic loss and/or point mutations has
turned out to be a recurrent event in cancer evolution. Loss of
function of the SETD2 tumor suppressor gene, which encodes the
only histone methyltransferase that can catalyze H3K36Me3, was
first identified in clear cell renal cell carcinomas,35 and subse-
quently, albeit at lower frequency, in several other solid tumors
including lung, breast, skin and brain cancers.36 More recently,
SETD2 loss of function and global loss of H3K36Me3 have been
observed in acute lymphoid and myeloid leukemias.37,38 In renal
cell carcinomas, SETD2 loss of function mainly results from large
monoallelic deletions or CN-LOH at chromosome 3p, followed by
mutation of the remaining allele.33 In acute leukemias, it rather
derives from biallelic missense or truncating mutations. Here, we
report for the first time that SETD2 and H3K36Me3 deficiency are
recurrent events in patients with advanced SM. Of note, our
findings demonstrate that SETD2 loss of function may also occur
at the post-translational level, in the absence of mutations or
structural aberrations. Biallelic inactivating mutations were indeed
found only in the index case. LOH of a relatively small region at
3p21.3 was detected in almost 50% of the patients of the
validation cohort, with higher frequency in advanced SM as
compared to ISM. However, LOH was neither associated with
coding, splicing or promoter mutations, nor with epigenetic
silencing, and no significant differences in SETD2 mRNA levels
were found when comparing SM patients with or without LOH
and healthy donors. Nonetheless, the great majority of the
patients had reduced SETD2 protein expression, albeit to a varying
degree, as compared to a pool of healthy donors as assessed by
western blotting. As expected, this was mirrored by similarly
reduced, or totally abrogated, H3K36Me3 (Figure 2a). IHC in BM
biopsies of the same patients further confirmed this observation
and showed weak or no nuclear staining for SETD2 in neoplastic
MCs (Supplementary Figure 2).
Very low or absent SETD2 protein expression was especially
found in cases with advanced SM (Figure 2b), with some
exceptions. The most striking outliers were three ISM patients
with no SETD2 expression by western blotting and IHC: one of
these patients was a severely symptomatic ISM case, with
histologically documented gastrointestinal involvement; one had
diffuse osteoporosis; the remaining one seemed to have no
peculiar clinical features. The small number of patients belonging
to each disease subtype limited the possibility to perform
statistical comparisons to identify peculiar clinical features or
outcome differences between patients with high vs low SETD2
expression within the ASM and ISM groups. When patients with
high and low SETD2 levels were compared irrespective of the
WHO category, lower SETD2 levels correlated with older age,
higher serum tryptase levels, lower hemoglobin and platelet
count, splenomegaly and absence of skin lesions. There was also a
not statistically significant trend towards shorter overall survival. In
Figure 4. Ubiquitinated and SUMOylated SETD2 after proteasome inhibition by bortezomib in HMC-1 cells (a) and in SM patients (b).
Co-immunoprecipitation (IP) with an anti-SETD2 antibody and immunoblotting (western blotting) with anti-ubiquitin and anti-SUMO
antibodies performed before and after bortezomib treatment (10 nM for 24 h). H3K36Me3 levels were also assessed by WB. H3 and beta-actin
were used as controls. The two ISM patients had near-normal SETD2 protein levels (90.5% and 75.8% of SETD2 expression with respect to a
pool of healthy donors); the MCL patient had no SETD2 protein expression (see Supplementary Table 3 for SETD2 protein level estimates as
assessed by densitometric analysis of western blots). One of three independent experiments is shown in all panels.
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this regard it is noteworthy that in renal cell carcinomas lower
SETD2/H3K36Me3 levels, assessed by IHC, correlate with larger
tumor burden, more advanced stage of disease, and a worse
prognosis.39,40 Similarly, in chronic lymphocytic leukemia recent
data suggest that SETD2 monoallelic deletions or mutations are
associated with inferior progression-free and overall survival.41
Analysis of a larger series of patients is warranted to fully
understand the clinical and prognostic meaning of SETD2 loss of
function in SM.
Proteasomal degradation was found to have a major role in the
observed lack of SETD2 protein. In the HMC-1 cell line and in
neoplastic MCs from advanced SM patients, incubation with the
proteasome inhibitor bortezomib rescued SETD2 expression and
H3K36Me3. Immunoprecipitation and immunoblotting showed
that blockage of proteasomal degradation results in accumulation
of ubiquitinated and SUMOylated SETD2 in HMC-1 cells and in
primary MCs in advanced SM patients with no SETD2 protein
expression but not in ISM patients with near-normal SETD2. This
evidence of ‘non-genomic’ loss of function suggests that
measuring protein and H3K36Me3 levels by western blotting or
IHC is the most informative screening approach and that the
frequency of SETD2 involvement in solid tumors or hematologic
malignancies might be higher than sequencing and copy number
data alone would suggest.
Figure 5. Effects of bortezomib and AZD1775+midostaurin combination in HMC-1 cells. (a and b) reduction of clonogenic growth of HMC-1.1
(red curve) and -1.2 (blue curve) cells, in the presence of increasing doses of bortezomib (0.25–1 nM) and AZD1775+midostaurin (0.025–0.1 μM),
respectively. All the clonogenic survival rates are expressed as mean± standard deviation of counts from three independent experiments.
Curves with AZD1775 (0.025–0.1 μM) and midostaurin (0.025–0.1 μM) as single agents are shown in c and d. (e) comparison of LD50 values for
the different strategies. (f and g) Induction of apoptosis in HMC-1.1 and -1.2, respectively. Columns represent the mean of three independent
experiments and the bars represent the standard error. ctrl, control; mido, midostaurin.
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Patients with evidence of LOH at 3p21.3 did not always harbor
lower SETD2 protein levels as compared to patients with no LOH.
Thus, the biological significance of the recurrent 3p21.3 LOH
events that can be observed in SM remains, at present, unclear.
Ligand-independent activation of the KIT pathway, often
resulting from the D816V KIT mutation, has a central role in SM
pathogenesis. In acute myeloid leukemias, SETD2 has been found
to be a critical cooperating event for a variety of major
chromosomal or genetic aberrations that are known to be driver
mutations in leukemogenesis.37 In these studies, SETD2 knock-
down contributed to leukemia initiation, accelerated progression,
enhanced the number and the self-renewal potential of leukemic
stem cells and was associated with increased expression of mTOR
and JAK-STAT pathway components—which are also important
downstream effectors of KIT. It can be hypothesized that reduced
SETD2 expression/absence and H3K36Me3 deficiency can coop-
erate with, and potentiate the effects of KIT constitutive activation
to determine the phenotype of advanced SM. Increased DNA
damage,42 reported to occur in SETD2-deficient cells, would then
be responsible for the accumulation of additional molecular/
cellular defects accounting for the phenotypic and clinical
heterogeneity of the disease.
Our findings may have important therapeutic implications.
Polychemotherapy, interferon, cladribine or midostaurin are
currently the main options in advanced SM, and hematopoietic
stem cell transplant is also considered in younger patients.43–45
However, treatment results are often unsatisfactory and many
patients relapse on therapy or have resistant disease. In addition,
in many cases with advanced SM-intensive therapy cannot be
applied because of age or poor performance status. As a result,
the prognosis of patients with advanced SM is poor and the
median survival of patients with MCL is measurable in months.
Our study points to bortezomib as a promising novel approach
worth exploring clinically for the treatment of advanced SM.
Bortezomib had already been reported to counteract the growth
of cell lines and primary neoplastic MCs, an effect that had been
attributed to the bortezomib-mediated re-expression of the pro-
apoptotic factor BIM (suppressed in SM as a result of constitutive
activation of the KIT/SCF pathway).46 However, the concentrations
of bortezomib required to suppress proliferation and induce
apoptosis were slightly lower than that required to re-express BIM,
which had led to the hypothesis that bortezomib might act in part
via additional mechanisms. We here show that bortezomib
treatment at subnanomolar concentrations promotes SETD2
protein re-expression, reduces clonogenic potential and promotes
apoptosis. Whether concomitant KIT D816V inhibition by mid-
ostaurin might exert an additive or synergistic effect was also
tested—but the striking efficacy of bortezomib as single agent
appeared not to be significantly enhanced further (Supplementary
Figure 3). In renal cell carcinomas, it has been reported that
SETD2-negative cells display elevated DNA damage42 and that
SETD2 depletion abrogates p53 activation.47 It can be
Figure 6. Reduction of clonogenic growth of neoplastic MCs from two patients with MCL (MCL3 and MCL7; blue and green curves,
respectively) and one patient with ASM (ASM18; red curve) as compared to two healthy donors (HDs; black and gray curves) in the presence of
increasing doses of bortezomib (0.25–1 nM) (a), AZD1775+midostaurin combination (0.025–0.1 μM) (b), AZD1775 alone (0.025–0.1 μM) (c),
midostaurin alone (0.025–0.1 μM) (d). All the clonogenic survival rates are expressed as mean± s.d. of counts from three independent
experiments. (e) Comparison of LD50 values for the different strategies.
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hypothesized that apoptosis triggered by bortezomib may at least
in part result from restoration of a functional p53 checkpoint in a
context of DNA damage.
We were also intrigued by the recent report suggesting that
H3K36Me3-deficient tumors can be targeted in vitro and in vivo by
AZD1775 (a Wee1 kinase inhibitor) through a mechanism of
synthetic lethality ultimately resulting in dNTP starvation.34
AZD1775 alone or in combination with other targeted drugs or
chemotherapy is currently being assessed in phase 2 studies for
several types of solid tumors as well as for acute leukemias and
myelodysplasias—which would greatly facilitate its repurposing.
This prompted us to explore whether the elimination of
H3K36Me3-deficient cells by AZD1775, alone or in combination
with KIT D816V inhibition by midostaurin, might prove effective
in vitro in our cell line model as well as in neoplastic MCs from
patients with advanced SM. AZD1775 and midostaurin showed
strong synergy in inducing apoptosis in HMC-1.1 cells, but only an
additive effect in HMC-1.2 cells. Clonogenic growth of both cell
line subclones was affected in a dose-dependent manner by
AZD1775+midostaurin combination, that was slightly more
effective than the single agents alone. In neoplastic MCs from
patients with advanced SM, the combination of AZD1775
+midostaurin appeared to be slightly superior to the single agent
strategy in two out of three cases, whereas in the remaining case
AZD1775 as single agent showed the lowest LD50. Additional
testing in a greater number of patient samples will thus be
required to better investigate the efficacy of a strategy using
AZD1775 alone or in combination.
In conclusion, we show that non-genomic loss-of-function of
SETD2 is a recurrent event in advanced SM. SETD2 and H3K36Me3
deficiency might cooperate with the ligand-independent activa-
tion of the KIT pathway to enhance leukemic transformation and
progression and determine the phenotype of ASM and MCL.
Targeting SETD2 down-modulation itself (with bortezomib or
second-generation proteasome inhibitors) and/or SETD2/KIT
cooperation are promising therapeutic strategies to improve the
outcome of ASM and MCL patients.
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